|23.52 -0.71 (-2.93%)||12-05 16:00|
|Targets||6-month :||28.97||1-year :||33.83|
|Resists||First :||24.8||Second :||28.97|
|Supports||First :||20.59||Second :||18|
|MAs||MA(5) :||23.6||MA(20) :||21.7|
|MA(100) :||26.92||MA(250) :||25.52|
|MACD||MACD :||0.1||Signal :||-0.5|
|%K %D||K(14,3) :||86.5||D(3) :||91.2|
|52-week||High :||35.59||Low :||15.43|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RVMD ] has closed below upper band by 20.2%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||24.11 - 24.24||24.24 - 24.35|
|Low:||23.06 - 23.23||23.23 - 23.36|
|Close:||23.27 - 23.52||23.52 - 23.73|
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||164 (M)|
|Held by Insiders||1.0697e+008 (%)|
|Held by Institutions||1.7 (%)|
|Shares Short||10,870 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-1 %|
|Return on Assets (ttm)||409.7 %|
|Return on Equity (ttm)||-25.5 %|
|Qtrly Rev. Growth||2.617e+007 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||-29.69|
|Qtrly Earnings Growth||-3.3 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-292 (M)|
|Price to Book value||0|
|Price to Sales||-0.8|
|Price to Cash Flow||4.51|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|